Financial TimesFinancial Times

Covid vaccine winners set sights on flu as their next big target

By Hannah Kuchler and Leila Abbud

23 Dec 2021 · 4 min read

After having beaten established vaccine makers to produce the first Covid-19 shots, Moderna and BioNTech, with its partner Pfizer, are racing to dethrone them in another big market: flu.

They are betting that the new messenger RNA technology used in their Covid vaccines at large-scale for the first time, will eventually allow flu jabs to be developed more quickly to match ever-changing annual strains and improve efficacy rates of between 40 and 70 per cent.

Sign in to informed

  • Curated articles from premium publishers, ad-free
  • Concise Daily Briefs with quick-read summaries
  • Read, listen, save for later, or enjoy offline
  • Enjoy personalized content